| 0.9 -0.034 (-3.64%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.25 |
1-year : | 1.43 |
| Resists | First : | 1.07 |
Second : | 1.23 |
| Pivot price | 0.91 |
|||
| Supports | First : | 0.82 | Second : | 0.69 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.93 |
| MA(100) : | 1.11 |
MA(250) : | 1.95 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 23.4 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 6.98 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENVB ] has closed above bottom band by 36.8%. Bollinger Bands are 70.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.96 | 0.96 - 0.97 |
| Low: | 0.87 - 0.87 | 0.87 - 0.88 |
| Close: | 0.89 - 0.9 | 0.9 - 0.91 |
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Fri, 12 Apr 2024
What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock - Zacks Investment Research
Mon, 01 Apr 2024
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023 - InvestorPlace
Tue, 05 Mar 2024
Should You Sell Enveric Biosciences Inc (ENVB) Stock Tuesday Morning? - InvestorsObserver
Thu, 29 Feb 2024
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of ... - Business Wire
Thu, 29 Feb 2024
Is Enveric Biosciences Inc (ENVB) Stock a Attractive Value? - InvestorsObserver
Thu, 29 Feb 2024
Enveric Biosciences Plans to Out-License Compound Classes - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 255 (K) |
| Shares Short P.Month | 95 (K) |
| EPS | -8.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.2 % |
| Return on Equity (ttm) | -197.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 1.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|